These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 38681989)

  • 1. Interplay between metabolic dysfunction-associated fatty liver disease and renal function: An intriguing pediatric perspective.
    Nardolillo M; Rescigno F; Bartiromo M; Piatto D; Guarino S; Marzuillo P; Miraglia Del Giudice E; Di Sessa A
    World J Gastroenterol; 2024 Apr; 30(15):2081-2086. PubMed ID: 38681989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.
    Yilmaz Y; Byrne CD; Musso G
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):345-352. PubMed ID: 33270482
    [No Abstract]   [Full Text] [Related]  

  • 3. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease.
    Zhang L; El-Shabrawi M; Baur LA; Byrne CD; Targher G; Kehar M; Porta G; Lee WS; Lefere S; Turan S; Alisi A; Weiss R; Faienza MF; Ashraf A; Sundaram SS; Srivastava A; De Bruyne R; Kang Y; Bacopoulou F; Zhou YH; Darma A; Lupsor-Platon M; Hamaguchi M; Misra A; Méndez-Sánchez N; Ng NBH; Marcus C; Staiano AE; Waheed N; Alqahtani SA; Giannini C; Ocama P; Nguyen MH; Arias-Loste MT; Ahmed MR; Sebastiani G; Poovorawan Y; Al Mahtab M; Pericàs JM; Reverbel da Silveira T; Hegyi P; Azaz A; Isa HM; Lertudomphonwanit C; Farrag MI; Nugud AAA; Du HW; Qi KM; Mouane N; Cheng XR; Al Lawati T; Fagundes EDT; Ghazinyan H; Hadjipanayis A; Fan JG; Gimiga N; Kamal NM; Ștefănescu G; Hong L; Diaconescu S; Li M; George J; Zheng MH
    Med; 2024 Jul; 5(7):797-815.e2. PubMed ID: 38677287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAFLD as part of systemic metabolic dysregulation.
    Zhao J; Liu L; Cao YY; Gao X; Targher G; Byrne CD; Sun DQ; Zheng MH
    Hepatol Int; 2024 Oct; 18(Suppl 2):834-847. PubMed ID: 38594474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated fatty liver disease is an early predictor for testosterone deficiency in aging men without metabolic syndrome.
    Liu CC; Huang SP; Lee YC; Lee CH; Huang TY; Geng JH; Chang CW; Lin CY; Juan YS; Wu WJ; Hsieh TJ
    Front Endocrinol (Lausanne); 2023; 14():1252774. PubMed ID: 37854195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
    Eslam M; Alkhouri N; Vajro P; Baumann U; Weiss R; Socha P; Marcus C; Lee WS; Kelly D; Porta G; El-Guindi MA; Alisi A; Mann JP; Mouane N; Baur LA; Dhawan A; George J
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):864-873. PubMed ID: 34364544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations.
    Theofilis P; Vordoni A; Kalaitzidis RG
    World J Gastroenterol; 2022 Oct; 28(39):5691-5706. PubMed ID: 36338895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic developments in metabolic dysfunction-associated fatty liver disease.
    Shi Y; Fan J
    Chin Med J (Engl); 2022 May; 135(9):1009-1018. PubMed ID: 35234696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
    Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
    Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit.
    Fabris L; Campello E; Cadamuro M; Simioni P
    Biochim Biophys Acta Mol Basis Dis; 2024 Mar; 1870(3):166763. PubMed ID: 37951510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coexistence of Metabolic Dysfunction-Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease.
    Miyamori D; Tanaka M; Sato T; Endo K; Mori K; Mikami T; Hosaka I; Hanawa N; Ohnishi H; Furuhashi M
    J Am Heart Assoc; 2023 Jul; 12(14):e030269. PubMed ID: 37421273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease.
    Lim S; Kim JW; Targher G
    Trends Endocrinol Metab; 2021 Jul; 32(7):500-514. PubMed ID: 33975804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome.
    Abenavoli L; Scarlata GGM; Scarpellini E; Boccuto L; Spagnuolo R; Tilocca B; Roncada P; Luzza F
    Medicina (Kaunas); 2023 Mar; 59(3):. PubMed ID: 36984595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD - common aspects of pathogenesis.
    Nováková B
    Cas Lek Cesk; 2022; 161(2):65-71. PubMed ID: 35728960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease in obese youth with insulin resistance and type 2 diabetes.
    Mastromauro C; Polidori N; Giannini C
    Curr Opin Pediatr; 2022 Aug; 34(4):414-422. PubMed ID: 35836399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease.
    Zhang W; Song WJ; Chen W; Pan Z; Zhang J; Fan L; Li J
    Eur J Gastroenterol Hepatol; 2024 Jun; 36(6):802-810. PubMed ID: 38526946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.